Huiying Medical Technology (Beijing)

Huiying Medical Technology, commercially known as HY Medical, was established in 2015 by Dr. Chai Xiangfei. Dr. Chai, who previously served as a postdoctoral researcher at Stanford University's Department of Radiation Oncology, brought a deep scientific background to the venture, which has since transitioned towards a strong business focus on market viability and monetization. The company is a key player in China's artificial intelligence medical imaging sector, leveraging computer vision and deep learning to enhance radiological diagnostics.

The firm's business model centers on providing AI-powered software solutions to healthcare institutions, primarily hospitals, which are its main paying clients. HY Medical has developed a suite of products designed to create a closed loop for patient care, from initial screening and diagnosis to treatment planning. Its offerings include the Dr. Turing AI platform for computer-aided diagnosis, the Radcloud for big data analytics and research, and the Novacloud smart imaging cloud for teleradiology and data sharing. These platforms assist radiologists by improving the efficiency and accuracy of interpreting medical images for numerous diseases, including providing automated lesion segmentation and structured reports. For instance, its COVID-19 screening system was developed using data from over 4,000 confirmed cases and could process a CT study in seconds with high accuracy.

Financially, HY Medical is venture capital-backed, having successfully navigated multiple funding rounds. Its first round was in 2015, and it has since secured investments from prominent firms such as Intel Capital, CDH, Delta Capital, and BlueRun Ventures. A significant Series B round in 2017 raised hundreds of millions of yuan, and a later strategic investment was led by Intel Capital in 2018. The company collaborates with over 800 medical institutions, focusing on integrating its technology into their existing workflows to support single-disease diagnosis and treatment across various specialties. This collaborative approach has led to the development of specialized platforms, such as the AI Full Cycle Health Management Cloud Platform for breast cancer and aortic diseases.

Keywords: medical imaging AI, computer vision, deep learning, radiological diagnostics, AI-assisted diagnosis, healthcare software, clinical decision support, medical data analysis, CT scan analysis, teleradiology, digital pathology, Dr. Turing platform, Radcloud, Novacloud, Chai Xiangfei, medical AI research, patient-oriented diagnosis, breast cancer AI, aorta AI, COVID-19 diagnosis AI